Animal Model News and Research

RSS

NIH Director announces seven new scientific programs scheduled to begin during fiscal year 2010

Programs to create a new center for the study of stem cells and to increase capacity to deal with global health issues were among seven scientific initiatives announced today by NIH Director Francis S. Collins, M.D., Ph.D. The seven research programs are supported through the NIH Common Fund, which encourages collaborative research programs across the NIH institutes and centers, or ICs, to accomplish work that no single IC could do alone.

26 Feb 2010

Comprehensive development strategy yields two potential drugs that block cancer-promoting pathways

A comprehensive drug development strategy that starts with extensive screening of potential targeting agents and then narrows down to a small-molecule prototype has yielded two potential drugs that block cancer-promoting pathways in novel ways, a team led by scientists at The University of Texas M. D. Anderson Cancer Center reports in two papers published back-to-back online at the Proceedings of the National Academies of Science.

26 Feb 2010

Schizophrenia: Insight into late development of symptoms

In reports of two new studies, researchers led by Johns Hopkins say they have identified the mechanisms rooted in two anatomical brain abnormalities that may explain the onset of schizophrenia and the reason symptoms don't develop until young adulthood. Both types of anatomical glitches are influenced by a gene known as DISC1, whose mutant form was first identified in a Scottish family with a strong history of schizophrenia and related mental disorders. The findings could lead to new ways to treat, prevent or modify the disorder or its symptoms.

26 Feb 2010

CHOP and AIAM collaborate to develop more accurate child crash test dummies

A research report released today by The Children's Hospital of Philadelphia (CHOP) and the Association of International Automobile Manufacturers, Inc. (AIAM) details CHOP's cutting-edge work with academic and industry collaborators to develop more accurate child crash test dummies, called child anthropometric test devices (ATD's).

25 Feb 2010

Rapamycin may hold promise for Alzheimer's disease

Rapamycin, a drug that keeps the immune system from attacking transplanted organs, may have another exciting use: fighting Alzheimer's disease.

25 Feb 2010

Information on early brain development and the importance of sleep during early life to be presented

Marcos Frank, PhD, associate professor of Neuroscience at the University of Pennsylvania School of Medicine, will present information on early brain development and the importance of sleep during early life when the brain is rapidly maturing and highly changeable.

22 Feb 2010

Unusual compounds in pitcher plant could prove effective against human fungal infections

The moment insects like flies, ants and beetles fall into a pitcher, the plant's enzymes are activated and begin dissolving their new meal, obtaining nutrients such as carbon and nitrogen which are difficult to extract from certain soils.

19 Feb 2010

NanoViricides signs research and development agreement with Dr. Eva Harris’s laboratory at UC Berkeley

NanoViricides, Inc. (the "Company"), reports that it has signed a research and development agreement with Dr. Eva Harris’s laboratory at the University of California, Berkeley (UC Berkeley).

17 Feb 2010

TB's mechanism to evade body's immune system identified

Indiana University School of Medicine researchers have identified a mechanism used by the tuberculosis bacterium to evade the body's immune system and have identified a compound that blocks the bacterium's ability to survive in the host, which could lead to new drugs to treat tuberculosis.

16 Feb 2010

Antibodies also contribute to severe dengue virus-induced disease, confirms La Jolla Institute for Allergy & Immunology

A leading immunology research institute has validated the long-held and controversial hypothesis that antibodies - usually the "good guys" in the body's fight against viruses - instead contribute to severe dengue virus-induced disease, the La Jolla Institute for Allergy & Immunology announced today. The finding has major implications for the development of a first-ever vaccine against dengue virus, a growing public health threat which annually infects 50 to 100 million people worldwide, causing a half million cases of the severest form.

12 Feb 2010

NNK induces epigenetic alteration during cancer formation and inhibits tumor suppressor genes

In the history of humans fighting against cancer, the relationship between tobaccos and cancer has been an important subject for the academic and clinical research. By understanding the mechanism of why cancer is caused by tobaccos, scientists around the world all anticipate to solve the mystery of cancer and find the way of prevention and cure.

9 Feb 2010

Marijuana ineffective against Alzheimer's disease in animal model

The benefits of marijuana in tempering or reversing the effects of Alzheimer's disease have been challenged in a new study by researchers at the University of British Columbia and Vancouver Coastal Health Research Institute.

8 Feb 2010

Investigational drug for osteoporosis inhibits serotonin synthesis in the gut

An investigational drug that inhibits serotonin synthesis in the gut, administered orally once daily, effectively cured osteoporosis in mice and rats reports an international team led by researchers from Columbia University Medical Center, in the Feb. 7 issue of Nature Medicine.

7 Feb 2010

Access Pharmaceuticals initiates Cobalamin technology program for targeted delivery of siRNA therapies

ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.

5 Feb 2010

PLX cell therapy may be an effective treatment for ischemic stroke disorder

Pluristem Therapeutics Inc. today announced that the results of a pre-clinical study in an animal model of ischemic stroke demonstrated that its PLacental eXpanded (PLX) cell therapy may be an effective treatment for this disorder.

4 Feb 2010

Study evaluates hepatocyte transplantation as an alternative to liver transplantation

A research team from the National Taiwan University Hospital has evaluated the efficiency of transplanted hepatocyte (liver) cells in animal models severely damaged by two kinds of chemical toxicity to see whether and how transplanted hepatocytes were able to efficiently repopulate the toxin-induced, severely damaged livers.

2 Feb 2010

Researchers design bioactive nanomaterial that promotes cartilage growth

Northwestern University researchers are the first to design a bioactive nanomaterial that promotes the growth of new cartilage in vivo and without the use of expensive growth factors. Minimally invasive, the therapy activates the bone marrow stem cells and produces natural cartilage.

1 Feb 2010

Study sheds light on pancreatic cancer development and new potential drug targets

Researchers at the Moores Cancer Center at the University of California, San Diego, have found one reason that pancreatic cancer tumors are so difficult to treat with drugs. They have shown how a molecular switch steps up pancreatic cancer cell survival as well as resistance to a standard chemotherapy drug, and have identified alternate routes cancer cells take to avoid the effects of the therapy.

29 Jan 2010

AKD Global announces new class of cancer treatments in development

AKD Global announced today the discovery of a new class of cancer treatments in development, providing hope for millions of sufferers. The spectacular results demonstrate a highly potent effect on cancer cells with no toxicity to healthy tissue. AKD is raising funds to continue development.

22 Jan 2010

COTI's novel small molecule effective against pancreatic cancer in animal model

Critical Outcome Technologies Inc. announced more positive results today from animal experiments carried out at a prominent Canadian cancer research facility. This new series of experiments adds to the impressive data package for COTI-2, demonstrating efficacy both as a single agent and in combination with current first line therapies, as well as low toxicity in several different animal models of human cancers.

21 Jan 2010

Animal Model News and Research

NIH Director announces seven new scientific programs scheduled to begin during fiscal year 2010

Comprehensive development strategy yields two potential drugs that block cancer-promoting pathways

Schizophrenia: Insight into late development of symptoms

CHOP and AIAM collaborate to develop more accurate child crash test dummies

Rapamycin may hold promise for Alzheimer's disease

Information on early brain development and the importance of sleep during early life to be presented

Unusual compounds in pitcher plant could prove effective against human fungal infections

NanoViricides signs research and development agreement with Dr. Eva Harris’s laboratory at UC Berkeley

TB's mechanism to evade body's immune system identified

Antibodies also contribute to severe dengue virus-induced disease, confirms La Jolla Institute for Allergy & Immunology

NNK induces epigenetic alteration during cancer formation and inhibits tumor suppressor genes

Marijuana ineffective against Alzheimer's disease in animal model

Investigational drug for osteoporosis inhibits serotonin synthesis in the gut

Access Pharmaceuticals initiates Cobalamin technology program for targeted delivery of siRNA therapies

PLX cell therapy may be an effective treatment for ischemic stroke disorder

Study evaluates hepatocyte transplantation as an alternative to liver transplantation

Researchers design bioactive nanomaterial that promotes cartilage growth

Study sheds light on pancreatic cancer development and new potential drug targets

AKD Global announces new class of cancer treatments in development

COTI's novel small molecule effective against pancreatic cancer in animal model

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News